论文部分内容阅读
目的:分析腹腔镜膀胱癌根治术的临床疗效及对血清铁蛋白(SF)、可溶性白介素-2受体(SIL-2R)、肿瘤特异性生长因子(TSGF)的影响。方法:选择2012年8月~2016年2月于我院就诊的98例膀胱癌患者,参照抽签法分作对照组(n=49)与研究组(n=49),对照组采用开放性膀胱癌根治术治疗,研究组采用腹腔镜膀胱癌根治术治疗,观察两组手术时间、术中出血量、肛门排气时间、住院时间、淋巴结清扫数目,SF、SIL-2R、TSGF,白细胞数、皮质醇,并发症率及复发率。结果:研究组手术时间多于对照组,研究组术中出血量、肛门排气时间、住院时间均少于对照组,组间差异有统计学意义(P<0.05)。两组淋巴结清扫数目、复发率比较无差异(P<0.05)。术后,两组SF、SIL-2R、TSGF均降低,组间比较无差异(P>0.05),两组白细胞数、皮质醇均上升,研究组低于对照组(P<0.05)。结论:LRC与ORC的临床疗效相似,均可降低血清SF、SIL-2R、TSGF水平,但LRC的创伤较小,在严格掌握适应症的情况下可作为膀胱癌的首选方式。
Objective: To analyze the clinical effects and the effects on serum ferritin (SF), soluble interleukin-2 receptor (SIL-2R) and tumor specific growth factor (TSGF) in laparoscopic radical mastectomy of bladder cancer. Methods: A total of 98 patients with bladder cancer treated in our hospital from August 2012 to February 2016 were selected and divided into control group (n = 49) and study group (n = 49) according to the drawing method. The control group was treated with open bladder The patients in the study group were treated with laparoscopic radical mastectomy. The operation time, intraoperative blood loss, anal exhaust time, hospitalization time, number of lymph node dissection, SF, SIL-2R, TSGF, leukocyte count, Cortisol, complication rate and recurrence rate. Results: The operation time of the study group was more than that of the control group. The bleeding volume, anal exhaust time and hospital stay in the study group were all less than those in the control group. There was significant difference between the two groups (P <0.05). There was no difference in the number of lymph node dissection and recurrence between the two groups (P <0.05). The levels of SF, SIL-2R and TSGF in both groups decreased after operation. There was no difference between the two groups (P> 0.05). The number of white blood cells and cortisol increased in both groups. Conclusion: The clinical efficacy of LRC and ORC are similar, both can reduce the serum levels of SF, SIL-2R and TSGF. However, the trauma of LRC is small, and can be used as the first choice of bladder cancer under strict indications.